We provide our clients with the top quality advice in order to make informed decisions in rapidly evolving life sciences and healthcare markets. We specialize in three areas of strategy consulting:
We are at a cusp of some major breakthroughs in biomedical sciences that will drive new and sustained growth in spending on healthcare products and services. At Zaylan, we provide deep expertise in strategic advice that enables executives to develop an informed strategy that will help them achieve profitable growth in the future. In particular, we help to addres 6 fundamental questions as part of our Strategy and Roadmap Development Practice :
- How are my customers’ needs and available market sizes changing over time?
- How do I segment the market in multiple ways to extract proprietary points of view on how the market segments are likely to evolve and which competitors are likely to win?
- How is the competitive landscape changing over time? Who are key threats?
- What capabilities do I need to compete for the next several years?
- What are adjacent markets I can enter ?
- Who do I acquire and how do I justify paying a premium?
- What is my growth roadmap to achieve my goals? ie. how do i achieve revenue targets through organic innovation, channel development and M&A
These are difficult questions that executives are confronted with on a continual basis. At Zaylan, we provide the expertise, the insights and a structured process to address such difficult questions.We have worked with both large global industrials, leading biopharma, leading diagnostics/med tech players as well as startups on developing growth strategies.
Today, most strategy consulting services are limited to market analysis and segmentation primarily by inexperienced analysts who typically do not have deep scientific grounding. In too many cases consulting teams are composed of junior staff with limited industry and science expertise and hence clients have been underwhelmed by the quality of the output. Moreover, there is an overreliance on public market reports to map out market landscape and segmentation. There is very little emphasis on developing a proprietary point of view on the markets and performing deep segmentation to arrive at unique perspectives on opportunities that may be unique to the client. We have also seen that most consulting firms do not have an objective process to perform deep internal capability analysis and thus are not able to link a market opportunity with a “hook” that may be unique to the client. Hence the output is generic and not grounded in deep market and scientific insights.
Another limitation is that digital business models are very challenging to dimensionalize given the nascent stage of these technologies. Too many times our clients have missed important market opportunities and failed to create digital businesses simply because they or their consultants were not able to “see” the opportunities. We have designed a process that has been pressure tested across many life sciences industries to create digital businesses.
Based on the above we believe there is a need for a new STRATEGY consulting approach.
We take a deep scientific approach in our strategy consulting. Our staff has deep scientific training and have been bring advanced degrees in medical and or biological sciences. Our teams have background in analytical techniques in Genomics/ Molecular Diagnostics ( qPCR Next gen Sequencing as well as digital PCR, FISH, Spatial transcriptomics,Gene Editing etc), Proteomics and Protein Diagnostics ( ELISA, flow cytometry, immunohistochemistry, western blotting, digital spatial profiling, LC and Mass Spec and other similar analytical approaches) and cell biology, (e.g. imaging, whole cell assays, biochemical assays, flow cytometry, cell manipulation approaches) . Our expertise spans from research, translational all the way to clinical and applied markets. In addition to analytical approaches, we also provide deep expertise in drug formulation delivery, Drug manufacturing as well as clinical trials. In the digital transformation area, we bring scientific and market understanding of how new digital approaches are impacting drug discovery all the way to clinical trials and patient care and diagnosis is being impacted
We create our own market models and research to have proprietary points of view on how markets are evolving and how to segment them. We have market models across all the disciplines highlighted in the previous points. On most projects, we bring market sizing and segmentation insights at the outset of the project
Most of our partners and staff have strategy consulting and industry experience and have applied and executive out strategy process not only has consultants but also has industry executives. We have had industry level expertise in respected companies such as Danaher, Philips and Illumina and have advised leading and emerging life sciences players from pharma, Med tech and Informations players
Our teams are staffed with consultants who bring deep industry experience, i.e. people who have built, sold and launched products and services in the Life sciences sectors. Our partners and consultants have prior executive level experience as players such as Danaher, Philips and Illumina.
This is core to our company and the reason we came into being in the first place. We have enabled digital businesses at leading medtech, pharma and life sciences tools players both organically and through M&A. This is a significant challenge for many players in Life sciences i.e., what problem to solve with digital approaches and how to generate new digital businesses and business models? Often, companies fail to see new opportunities simply because they are segmenting markets in traditional ways or not able to fully understand their internal workflow and processes that prevents them to create compelling business cases for innovation. We have developed strategy processes (from market segmentation to capability reviews and target analysis) that are suited to digital businesses. (see below for a chart on our Digital Strategy Process)
We are World class strategists with deep sector expertise and industry experience; our consultants bring practical experience as executives in leading life sciences companies including medtech players such as Illumina, Danaher, Philips as well as Pharma / Biopharma companies.
Pressure tested growth strategy process that has been deployed over the past 2 decades at world leading pharma/biotech, diagnostics. Medtech, CRO, health information as well as leading industrials to facilitate developing growth strategy, digital transformation strategy; in addition we are also working with leading consumer products companies to develop consumer health strategies
Pressure tested digital strategy process in order to develop priorities in digital initiatives; the only consulting firm that has concrete experience in developing digital strategy and deployed solutions at leading pharma, medtech, diagnostics as well as Life Sciences tool providers.